Understanding how progesterone receptor signaling affects estrogen-positive breast cancer
Progesterone Receptor (PR) Signaling Cross Talk Drives ER+ Breast Cancer
This study is looking at how different types of progesterone receptors affect the growth of estrogen-positive breast cancer, especially in cases where common treatments like tamoxifen aren't working, to find new ways to help patients with recurring breast cancer feel better and respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10774285 on NIH RePORTER |
What this research studies
This research investigates the role of progesterone receptors in estrogen-positive breast cancer, particularly how their signaling interactions can influence cancer growth and treatment resistance. The study focuses on the different isoforms of progesterone receptors and their effects on cancer cell behavior, especially in cases where traditional therapies like tamoxifen fail. By examining the mechanisms behind these interactions, the research aims to identify new therapeutic targets that could improve treatment outcomes for patients with recurrent breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with estrogen-positive breast cancer, especially those who have experienced recurrence or resistance to standard treatments.
Not a fit: Patients with other types of breast cancer or those who have not been diagnosed with estrogen-positive breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for estrogen-positive breast cancer, particularly for patients who experience recurrence after initial therapy.
How similar studies have performed: Previous research has shown promising results in understanding the role of progesterone receptors in breast cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Lange, Carol a — University of Minnesota
- Study coordinator: Lange, Carol a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.